eb513503b5
- Source: inbox/queue/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md - Domain: health - Claims: 2, Entities: 2 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
35 lines
No EOL
1.7 KiB
Markdown
35 lines
No EOL
1.7 KiB
Markdown
---
|
|
title: National Association of Anorexia Nervosa and Associated Disorders (ANAD)
|
|
type: entity
|
|
entity_type: organization
|
|
domain: health
|
|
status: active
|
|
---
|
|
|
|
# National Association of Anorexia Nervosa and Associated Disorders (ANAD)
|
|
|
|
Oldest U.S. eating disorder advocacy organization, founded 1976. Provides clinical guidance, support groups, and treatment resources.
|
|
|
|
## Timeline
|
|
|
|
- **2025-01-01** — Published joint clinical guidance with NEDA on GLP-1 receptor agonist use in eating disorder populations, documenting that GI side effects 'can trigger or worsen purging behaviors' and recommending tri-specialist care teams with hydration/electrolyte monitoring
|
|
|
|
## Overview
|
|
|
|
ANAD focuses on eating disorder treatment access, clinical standards, and patient advocacy. Their guidance documents clinical best practices but carries no regulatory authority.
|
|
|
|
## Key Clinical Positions
|
|
|
|
**GLP-1 Monitoring Requirements (2025):**
|
|
- Hydration and electrolyte levels (vomiting + GI side effects pose serious risk)
|
|
- Emergence of restrictive eating behaviors
|
|
- Weight loss rate and magnitude
|
|
- Eating disorder symptom changes via standardized measures
|
|
|
|
**Required Care Team:**
|
|
- Physician versed in GLP-1s and eating disorders
|
|
- Therapist experienced with both GLP-1s and ED treatment
|
|
- Dietitian familiar with this medication class and recovery nutrition
|
|
|
|
**Documented Risks:**
|
|
ANAD notes that GI side effects (nausea, vomiting, diarrhea, gastroparesis) 'can trigger or worsen purging behaviors' in vulnerable individuals, creating a direct pharmacological harm pathway. Approximately 2/3 of weight loss returns within one year if medication stops, creating weight cycling risk particularly harmful for ED populations. |